This review investigated the efficacy of third generation (3G) chemotherapy agents on response and survival in stage IIIB/IV non-small cell lung cancer. The authors found that 3G monotherapy improved one-year survival in comparison with best standard care, but a number of reporting and methodological limitations meant that these conclusions may not be reliable.
Study selection
Randomised controlled trials (RCTs) of patients diagnosed with advanced stage non-small cell lung cancer that had not received treatment previously were eligible for inclusion. The included patients had a median age of 58 to 74 years. Most were male (61 to 93%). The percentage of patients with stage IIIB disease varied from 0 to 61% and those with stage IV from 39% to 100% in the included studies. Treatment combinations eligible for inclusion were: 3G monotherapy versus best supportive care; 3G monotherapy versus second generation (2G) platinum-based regimen; and 3G platinum-based versus 2G platinum-based regimen (3G agents were defined as paclitaxel, docetaxel, gemcitabine, vinorelbine and irinotecan; 2G regimens were defined as platinum alone or platinum in combination with older agents including etoposide, vindesine, ifosfamide and mitomycin). The outcomes of interest were response to treatment and one-year survival rate. A variety of drugs and therapy classes were investigated in the included studies. All of the trials that compared 3G agents combined with platinum therapy with 2G regimens were published in 1994 or after.
Study selection was by consensus among reviewers. The authors did not state how many reviewers performed the study selection.
Assessment of study quality
The authors did not state that they assessed validity.
Data extraction
Data were extracted for response (overall, complete, partial, stable disease and progression) and one-year survival rate.
The authors did not state how data were extracted.
Methods of synthesis
Risk differences and corresponding 95% confidence intervals (CIs) were pooled as inverse variance weighted averages of estimates from each study. Studies were only pooled when there was little evidence of heterogeneity (p>0.1) or publication bias. Number needed to treat was calculated and survival at one year was based on intention to treat analysis and response rates based on assessable patients. Publication bias was investigated with funnel plots and Begg's Test. Statistical heterogeneity was assessed (test not described).
